Lab
Laboratorio Clinico Alfeciza INC.
Laboratorio Clinico Alfeciza INC. was paid $445K by Medicaid between Jan 2018 and Dec 2024, across 34 billing codes. Its largest line is G2023, Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source — 19% of everything it billed.
33Billing provider infoLABORATORIO CLINICO ALFECIZA INC.
VILLALBA, PUERTO RICO 00766
VILLALBA, PUERTO RICO 00766
33aNPI1356768246assigned 03/28/2014
33bProvider typeClinical Medical Laboratory
28Total paid$445K
24GClaims31,777
24DCodes billed34
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 4,032 | $33K | |
| 2019 | 2,937 | $20K | |
| 2020 | 3,510 | $64K | |
| 2021 | 7,096 | $124K | |
| 2022 | 5,532 | $104K | |
| 2023 | 6,006 | $71K | |
| 2024incomplete | 2,664 | $28K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 19% | 3,556 | 3,088 | $84K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 18% | 2,321 | 2,036 | $81K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 11% | 1,057 | 942 | $50K |
| 84443 | Thyroid stimulating hormone (TSH) | 9.3% | 2,756 | 2,583 | $42K |
| 80061 | Lipid panel | 7.1% | 2,672 | 2,472 | $31K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 5.9% | 3,990 | 3,506 | $26K |
| 80053 | Comprehensive metabolic panel | 5.7% | 2,670 | 2,444 | $25K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 4.1% | 1,618 | 693 | $18K |
| 86328 | 3.0% | 700 | 658 | $13K | |
| 81000 | 2.4% | 3,699 | 3,355 | $11K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 2.2% | 189 | 179 | $10K |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.7% | 913 | 832 | $8K |
22 more codes
| 36415 | Collection of venous blood by venipuncture | 1.7% | 1,266 | $8K |
| 86701 | 1.1% | 624 | $5K | |
| 85027 | <1% | 791 | $4K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 563 | $4K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 130 | $4K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 130 | $4K |
| 86738 | <1% | 346 | $4K | |
| 82274 | <1% | 272 | $3K | |
| 86592 | <1% | 607 | $2K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 75 | $2K |
| 87088 | <1% | 115 | $845.58 | |
| 84439 | <1% | 96 | $818.09 | |
| 84153 | <1% | 46 | $765.40 | |
| 82043 | <1% | 118 | $617.76 | |
| 82570 | <1% | 117 | $543.45 | |
| 82607 | <1% | 38 | $483.83 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 46 | $308.27 |
| 84550 | <1% | 22 | $103.87 | |
| 84460 | <1% | 19 | $102.87 | |
| 84450 | <1% | 19 | $100.67 | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 59 | $0.39 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 0% | 137 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialZAYAS, DAISY (DIRECTOR)